NasdaqCM - Delayed Quote • USD
Compare
At close: 6 August at 4:00 pm GMT-4
After hours: 6 August at 7:37 pm GMT-4
Line
Candle
Baseline
Mountain
Bar
Loading Chart for GNPX
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous close
1.5100 - Open
1.4550 - Bid --
- Ask --
- Day's range
1.4100 - 1.4996 - 52-week range
1.4100 - 28.8400 - Volume
25,802 - Avg. Volume
103,362 - Market cap (intra-day)
2.959M - Beta (5Y monthly) -0.51
- PE ratio (TTM)
-- - EPS (TTM)
-18.8100 - Earnings date 21 Aug 2024 - 26 Aug 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
165.00
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
26
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Biotechnology
Industry
More about Genprex, Inc.
Recent news: GNPX
View moreAll SEC filings
Corporate changes and voting matters
Periodic financial reports
Proxy statements
Tender offer/acquisition reports
Offering registrations
Performance overview: GNPX
Trailing total returns as of 06/08/2024, which may include dividends or other distributions. Benchmark is
YTD return
GNPX
84.67%
S&P 500
9.86%
1-year return
GNPX
95.08%
S&P 500
17.02%
3-year return
GNPX
98.82%
S&P 500
18.31%
5-year return
GNPX
96.25%
S&P 500
84.20%
Compare to: GNPX
Compare
Select to analyse similar companies using key performance metrics; select up to four stocks.
1.4100
-6.62%
Mkt cap 2.959M
Industry Biotechnology
0.9001
-4.80%
Mkt cap 26.839M
Industry Biotechnology
0.3080
+4.41%
Mkt cap 3.221M
Industry Biotechnology
2.2400
+8.47%
Mkt cap 100.211M
Industry Biotechnology
1.3400
+3.08%
Mkt cap 71.381M
Industry Biotechnology
Mkt cap 16.303M
Industry Biotechnology
0.9970
+10.04%
Mkt cap 1.988M
Industry Biotechnology
0.7299
+15.22%
Mkt cap 25.732M
Industry Biotechnology
3.3700
+3.69%
Mkt cap 2.814M
Industry Biotechnology
0.1299
-0.84%
Mkt cap 137.507M
Industry Biotechnology
0.7802
-63.37%
Mkt cap 42.629M
Industry Biotechnology
Statistics: GNPX
View more
Valuation measures
As of 05/08/2024
Market cap
3.09M
Enterprise value
-5.13M
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
--
Price/book (mrq)
0.35
Enterprise value/revenue
--
Enterprise value/EBITDA
0.18
Financial highlights
Profitability and income statement
Profit margin
0.00%
Return on assets (ttm)
-96.86%
Return on equity (ttm)
-202.83%
Revenue (ttm)
--
Net income avi to common (ttm)
-27.63M
Diluted EPS (ttm)
-18.8100
Balance sheet and cash flow
Total cash (mrq)
8.22M
Total debt/equity (mrq)
--
Levered free cash flow (ttm)
-13.02M
Research analysis: GNPX
View morePeople also watch
DARE Daré Bioscience, Inc.
3.2200
+0.31%
CODX Co-Diagnostics, Inc.
1.1100
+5.71%
COCP Cocrystal Pharma, Inc.
1.7500
0.00%
AIM AIM ImmunoTech Inc.
0.3235
+0.28%
AYTU Aytu BioPharma, Inc.
2.4500
+0.41%
OPGN OpGen, Inc.
2.2700
-11.33%
VTVT vTv Therapeutics Inc.
14.66
+0.90%
AGRX Agile Therapeutics, Inc.
1.4600
0.00%
NNVC NanoViricides, Inc.
2.0600
+1.98%
CTXR Citius Pharmaceuticals, Inc.
1.0200
+9.40%
PIXY ShiftPixy, Inc.
1.1500
-4.96%
CAPR Capricor Therapeutics, Inc.
3.9100
+3.71%
CLSD Clearside Biomedical, Inc.
1.0900
0.00%
HOTH Hoth Therapeutics, Inc.
0.6280
-0.81%
BSGM BioSig Technologies, Inc.
0.3500
+5.42%
VBIV VBI Vaccines Inc.
0.1329
+111.29%